Navigation Links
MannKind Corporation to Host Webcast Analyst Day September 16, 2008
Date:9/11/2008

Company To Review Data from First Pivotal Phase 3 Clinical Trial

VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it will host an analyst day for the investment community to review clinical results from Phase 3 and other clinical trials of the company's Technosphere(R) Insulin System. The meeting will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit the MannKind Corporation web site at http://www.mannkindcorp.com.

Mr. Al Mann and other members of MannKind's management will review the Phase 3 data, and the meeting will also feature John ("Jack") E. Gerich, M.D., a world renowned diabetologist and expert in the physiology of diabetes and glucose metabolism. Dr. Gerich is professor of medicine and physiology and director of the clinical research center at the University of Rochester School of Medicine.

About the Technosphere(R) Insulin System

MannKind's investigational inhaled insulin product consists of its proprietary Technosphere(R) particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using MannKind's proprietary MedTone inhaler. A long sought-after goal in the treatment of diabetes has been to produce a profile of insulin levels in the bloodstream that closely mimics the normal human physiologic insulin response. In clinical studies to date, the Technosphere(R) Insulin System has been consistently observed to produce peak insulin levels within 12-14 minutes of inhalation, which approximates the early insulin secretion normally seen in healthy individuals following the beginning of a meal. MannKind believes that the ability to produce a better approximation of normal insulin physiology translates into better glucose control, thereby giving this investigational product potential clinical and commercial advantages.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes Technosphere(R) Insulin, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Brooke Franchise Corporation Announces Selected July Results
9. MedThink Communications Retained by NanoBio Corporation
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
Breaking Medicine Technology: